Back

Applying the Latest Data and Expert Guidance for CSF1R-Targeted Treatment of TGCT

In this videobased module expert faculty examines evolving treatment strategies for tenosynovial giant cell tumor TGCT with emphasis on individualized decisionmaking for patients with symptomatic progressive or functionlimiting disease The activity reviews when observation surgery systemic therapy or combined approaches may be appropriate the limitations and potential morbidity of surgery particularly in diffusetype TGCT and phase III evidence from the ENLIVEN and MOTION trials investigating CSF1Rtargeted therapies In addition the faculty discusses emerging agents treatment duration and sequencing monitoring for progressive joint damage and the role of multidisciplinary care and shared decisionmaking in balancing disease control treatment burden toxicity quality of life and preservation of joint function

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.25 creditsAAPA Category 1 Credit™Up to 0.25 creditsAMA PRA Category 1 Credit™Up to 0.25 creditsNursingUp to 0.25 creditsPharmacyUp to 0.25 credits

MOC types

ABIM — Medical KnowledgeUp to 0.25 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • includes Online course / module
  • Credit · Up to 0.25 credits
  • MOC · Up to 0.25 points
  • Commercial Support
  • Released
    Aug 24, 2026
  • Last day to claim credit
    Feb 24, 2027 5 months left